We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+7.5%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$54.6M
AUM Growth
+$16.2M
(+42%)
Cap. Flow
+$14.4M
Cap. Flow
% of AUM
26.39%
Top 10 Holdings %
Top 10 Hldgs %
73.49%
Holding
23
New
7
Increased
7
Reduced
5
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$5.83M |
| 2 |
Centene
CNC
|
+$4.41M |
| 3 |
ALR
Alere Inc
ALR
|
+$2.77M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$2.71M |
| 5 |
PTC Therapeutics
PTCT
|
+$2.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XNPT
XENOPORT, INC.
XNPT
|
+$7.34M |
| 2 |
Quest Diagnostics
DGX
|
+$2.19M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$1.5M |
| 4 |
AERI
Aerie Pharmaceuticals
AERI
|
+$916K |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$727K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.09% |
| 2 | Miscellaneous | 2.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Centene
CNC
$34.3B
| $5.86M | 10.74% |
164,270
+140,570
| +593% | +$4.41M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$16B
| $5.59M | 10.23% |
+39,540
| New | +$5.83M |
|
3
Eli Lilly
LLY
$1.01T
| $4.64M | 8.51% |
58,965
-6,435
| -10% | -$484K |
|
|
4
Bio-Rad Laboratories Class A
BIO
$9.85B
| $4.44M | 8.13% |
31,029
+18,979
| +158% | +$2.71M |
|
5
Teva Pharmaceuticals
TEVA
$45.1B
| $4.19M | 7.68% |
83,502
+42,216
| +102% | +$2.25M |
|
|
NVRO
6
DELISTED
NEVRO CORP.
NVRO
| $3.73M | 6.84% |
50,633
+1,256
| +3% | +$85.2K |
|
7
UnitedHealth
UNH
$344B
| $3.34M | 6.12% |
23,648
+5,748
| +32% | +$766K |
|
|
8
Quest Diagnostics
DGX
$26.3B
| $2.84M | 5.2% |
34,843
-28,752
| -45% | -$2.19M |
|
9
Edwards Lifesciences
EW
$49.3B
| $2.82M | 5.16% |
84,810
+37,470
| +79% | +$1.28M |
|
|
ALR
10
DELISTED
Alere Inc
ALR
| $2.66M | 4.88% |
+63,905
| New | +$2.77M |
|
|
11
PTC Therapeutics
PTCT
$5.55B
| $2.15M | 3.94% |
+306,650
| New | +$2.25M |
|
12
Incyte
INCY
$24.8B
| $2.04M | 3.74% |
+25,510
| New | +$1.98M |
|
|
IPXL
13
DELISTED
Impax Laboratories, Inc.
IPXL
| $2.02M | 3.71% |
70,235
+8,185
| +13% | +$267K |
|
|
AERI
14
DELISTED
Aerie Pharmaceuticals
AERI
| $1.48M | 2.71% |
84,026
-56,561
| -40% | -$916K |
|
15
Pacira BioSciences
PCRX
$984M
| $1.41M | 2.58% |
+41,707
| New | +$2.05M |
|
|
16
Neurocrine Biosciences
NBIX
$16B
| $1.39M | 2.55% |
30,671
-32,517
| -51% | -$1.5M |
|
|
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
| $1.25M | 2.3% |
229,626
-103,887
| -31% | -$727K |
|
|
SGYP
18
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $1.13M | 2.08% |
+298,190
| New | +$1.01M |
|
19
OraSure Technologies
OSUR
$232M
| – | – |
-69,200
| Closed | -$500K |
|
20
QuidelOrtho
QDEL
$763M
| – | – |
-41,550
| Closed | -$717K |
|
|
XNPT
21
DELISTED
XENOPORT, INC.
XNPT
| – | – |
-1,627,628
| Closed | -$7.34M |
|
|
ANAC
22
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| – | – |
-8,850
| Closed | -$473K |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Asymmetry Capital Management held 23 positions worth $54.6M, up 42% from $38.4M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Asymmetry Capital Management deployed $14.4M of net new capital in Q2 2016, opening 7 new positions and adding to 7 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 39,540 shares worth $5.59M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 80% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Quest Diagnostics, an estimated $2.19M trimmed.
- Asymmetry Capital Management's largest Q2 2016 buy was Jazz Pharmaceuticals: 39,540 shares worth $5.59M.
- Asymmetry Capital Management added most to Centene in Q2 2016, an estimated $4.41M increase.
- Asymmetry Capital Management's biggest Q2 2016 reduction was Quest Diagnostics, cutting an estimated $2.19M.
- Asymmetry Capital Management fully exited XENOPORT, INC. in Q2 2016, selling an estimated $7.34M.
- Asymmetry Capital Management's ten largest holdings make up 73% of its $54.6M portfolio in Q2 2016.
- Asymmetry Capital Management opened 7 new positions and closed 4 in Q2 2016.
- Asymmetry Capital Management's portfolio value rose 42% quarter-over-quarter to $54.6M.
Based on Asymmetry Capital Management's 13F filing for Q2 2016, filed 5 Aug 2016.